Verrica’s Anticancer Efforts Kick Off With Promising Early Phase II BCC Data
In Handful Of Patients
Executive Summary
The US firm’s oncolytic peptide candidate, VP-315, has shown tumor clearance in a Phase II basal cell carcinoma trial, marking a positive start for its plans to expand from non-malignant dermatology to skin cancer.